Clinical trials: Irinotecan-induced Diarrhea
Colorectal Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Irinotecan is one of key drug used in the treatment of colorectal cancer. The incidence of irinotecan induced diarrhea varies between 60-90%, with severe diarrhea in 20-40%.
- Trial name
- NCT01410955
- Testing
- Probiotic formula
- Where
- 6 sites in Slovakia
- Volunteers
- 46 people
- Sponsor
- Monsea Ltd.
Diarrhea, Cancer
Prevention of Irinotecan Induced Diarrhea by Probiotics
Diarrhea is a relatively common complication in patients with cancer. At its inception, several mechanisms participated; malabsorption on the basis of mucositis induced by chemotherapy, dysbiosis induced by broad-spectrum…
- Trial name
- NCT02819960
- Testing
- Probio-Tec® BG-VCap-6.5
- Where
- Slovakia
- Volunteers
- 233 people
- Sponsor
- S&D Pharma SK s.r.o.
Chemotherapy-induced Diarrhea
Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.
- Trial name
- LARCID (NCT00582426)
- Testing
- Octreotide Long Acting Release, Standard Treatment
- Where
- 11 sites in Brazil
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Diarrhea
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
RATIONALE: Octreotide may be effective in preventing diarrhea that is caused by treatment with irinotecan. PURPOSE: Randomized phase III trial to study the effectiveness of octreotide in preventing diarrhea in patients who are…
- Trial name
- NCT00006269
- Testing
- irinotecan hydrochloride, octreotide acetate
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Novartis